IRIDEX Corporation (IRIX) is a small-cap medical technology company that develops laser consoles, delivery devices and disposable probes used in ophthalmology, with its core franchises in glaucoma (the Cyclo G6 and MicroPulse P3 platform) and retinal surgery (the PASCAL line). In late-morning trading Wednesday, the stock changed hands at $0.50, down 28.53% from the prior session's close of $0.6996 — a decisive move lower. The immediate reason is unambiguous: the company reported third-quarter 2026 results after Tuesday's close that fell well short of expectations on revenue and earnings and included a reduced full-year outlook.
The quarter ended October 3 produced revenue of $10.2 million, down about 19% from $12.5 million a year earlier and materially below the roughly $12.65 million consensus. The shortfall was concentrated overseas. International retina sales weakened across China, Japan and Europe, with China orders collapsing to about $400,000 from roughly $4 million a year earlier. Global Cyclo G6 probe volume slipped to approximately 11,900 units from 14,900, and system placements eased to 28 from 30. Management blamed order timing, distributor destocking ahead of the manufacturing relocation, and regulatory delays.
Earnings quality followed the top line. The GAAP net loss was $1.4 million, or $0.08 per share, wider than the $0.02 loss analysts modeled, and adjusted EBITDA swung to a loss of $0.6 million from $0.1 million a year earlier. Management cut its full-year 2026 revenue guidance to $46–$48 million from $51–$53 million, a reduction of roughly 10% at the midpoint, citing continued international volatility and regulatory timing. For a company valued near $9 million at today's price, a revision of that size is a major event rather than a routine update.
The cash picture reinforced the selling. Cash and equivalents fell to $3.7 million from $4.7 million at the end of the second quarter, and operating cash use was about $1 million as inventories swelled to $11.8 million to protect distributors during the facility transition. Total liabilities stood at $26.6 million against total assets of $29.3 million. With a thin cash cushion and an ongoing loss profile, the market is pricing dilution and financing risk more aggressively than the operating miss alone would justify.
Not every data point was negative, which is why the reaction is notable. Gross margin climbed to 42.4% from 32.1% a year earlier, a ten-point year-over-year improvement, helped by favorable geographic mix and pricing discipline. U.S. PASCAL revenue rose approximately 50% year over year, U.S. glaucoma pricing firmed, and the San Jose manufacturing relocation is complete, expected to deliver roughly $600,000 in annualized rent savings. Management is also conducting a strategic review of its product portfolio and distribution footprint and targets meaningful margin expansion and operating expense reductions in 2027. Investors are evidently unwilling to pay for that optionality while the revenue base is shrinking.
Volume was heavy. Roughly 160,000 shares had changed hands within the first 90 minutes of Wednesday's session, several times the stock's recent daily average of roughly 28,000–50,000 shares. The stock gapped open at $0.50 and traded in a range of about $0.47 to $0.53, putting it at its lowest levels of the past three months and roughly 30% below its 50-day average near $0.71. The move was not a sector event: a broad medical-device benchmark slipped about 0.3% and the large healthcare sector ETF fell about 1.6%, so the decline is idiosyncratic rather than a sympathy selloff. Analyst coverage is thin, with a single published rating, which tends to amplify post-earnings repricing in micro-caps.
On a scale where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news paired with an extreme, rare price move, IRIX scores 81 out of 100. The verified news was substantial: revenue and earnings both missed consensus and full-year guidance was cut by about 10% at the midpoint, a large revision for a company of this size. The reaction was equally unusual — today's 28.5% decline is roughly ten times the stock's typical 2.7% absolute daily move, and no single-session drop of comparable size has occurred in the past 60 sessions, where the worst was 8.7%.
Attention turns to the fourth quarter, which management expects to benefit from the release of remaining safety stock, deferred Japan PASCAL shipments worth about $300,000, open international orders and typical year-end seasonality. The lowered guidance implies quarterly revenue in the rough area of $11.5–$13.5 million, and management has said sequential and year-over-year growth in both probes and systems is expected. Key swing factors include European PASCAL MDR certification, now targeted for the first half of 2027, the pace of the contract-manufacturing transition, further operating expense reductions, and whether the strategic review results in portfolio exits. Principal risks are continued weakness in China, competitive pricing pressure in Europe, and the adequacy of a $3.7 million cash balance against an $11.8 million inventory position.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions make it into the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the specific symbols they trade, so the lineup rotates as market conditions shift. Investors looking for systematic, rules-based exposure can review the current leaders and compare approaches before deciding which fits their own objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 49 cases where IRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 67 cases where IRIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on IRIX as a result. In 73 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 150 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
IRIX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IRIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for IRIX entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.955) is normal, around the industry mean (4.142). P/E Ratio (-3.330) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of light-based medical systems and delivery devices
Industry MedicalNursingServices